efbemalenograstim alfa-vuxw (Ryzneuta)

Indications

• treatment of cytotoxic chemotherapy induced neutropenia

Contraindications

• serious allergic reactions to granulocyte stimulating factor
  • efbemalenograstim alfa, pegfilgrastim, filgrastim

* pregnancy: insufficient data

Dosage

• 20 mg SC once per chemotherapy cycle
  • given at least 24 hr after cytotoxic chemotherapy
  • do not administer within 14 days before or < 24 hr after administration of cytotoxic chemotherapy

20 mg/mL prefilled syringe

Adverse effects

• nausea (51%)
• anemia (15%)
• thrombocytopenia (12%

Mechanism of action

• granulocyte colony-stimulating factor

More general terms

• pharmaceutical growth factor
• granulocyte colony-stimulating factor